ModifiedColorado Rocky Mountain Health PlansPolicy CS046.S

Gastrointestinal Disorders Diagnostic Procedures

Defines coverage and medical necessity for diagnostic procedures used in gastrointestinal disorders and identifies procedures considered unproven or not medically necessary; applies to Colorado Rocky Mountain Health Plans members except where state-specific policies are listed.

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyGastrointestinal Disorders Diagnostic Procedures

Policy CodePolicy CS046.S

Change TypeContent revisions with material additions/removals

Effective DateApr 1, 2026

Next Review Date

Key ActionDocument prior conservative management and objective diagnostic evidence and obtain prior authorization when requesting procedures listed as unproven or experimental.

SourceLink

POLICY UPDATE CHANGES

Updated reference link to reflect the current title for state-specific policy version for North Carolina.

Title changed from 'Gastrointestinal Motility Disorders, Diagnosis and Treatment' as part of a template update.

Removed content/language pertaining to the state of Louisiana.

Removed and relocated language pertaining to gastric electrical stimulation (GES) therapy to a different medical policy.

Added 'Functional Lumen Imaging Probe (FLIP) technology for diagnosing Achalasia' to the list of unproven and not medically necessary procedures.

Removed examples listing Cutaneous, mucous, or serosal Electrogastrography, electroenterography, or body surface gastric mapping devices and MiVu Mucosal Integrity Testing System.

Updated Description of Services, Clinical Evidence, FDA, and References sections to reflect current information and removed Medical Records Documentation Used for Reviews section; archived previous policy version CS046.R.

4procedures listed as unproven/not medically necessary

9 codes

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

example procedure codes referenced

≈16%prevalence of constipation (adults)

≈33%prevalence (age >60)

CS046.Rarchived previous policy version

Coverage Criteria and Evidence Summary

Clinical Standards

Standard diagnostic expectations referenced:

Gastroparesis Diagnostic Standard: Diagnosis of gastroparesis requires objective evidence of clearly delayed gastric emptying in symptomatic patients; scintigraphy is the reference standard and adherence to standardized meal protocols and adequate imaging duration is necessary for valid interpretation.

For all gastrointestinal function tests, adherence to validated, standardized study protocols is crucial.

Guideline Context

Guideline context for FLIP:

Professional guideline positions on FLIP: Professional societies note FLIP may be useful in specific contexts (for example, when standard manometry cannot be completed because FLIP is performed during endoscopy under sedation) but clinicians should not make a diagnosis or treatment decision based on FLIP assessment alone; the role of FLIP is evolving and additional standardized protocols and studies are required.

AGA and ACG recommend FLIP be used as a complementary tool with distinct protocols and not as a sole diagnostic basis.

Clinical guidance and evidence summaries

Guidance and evidence-based conclusions present in this section:

FLIP use: FLIP may be useful for patients who cannot tolerate or complete standard manometry and as a complementary tool to assess esophagogastric junction opening dynamics and esophageal wall stiffness.

Do not make diagnosis or treatment decisions based on FLIP alone; the role is evolving and further studies are needed.

MRI defecography role: MRI defecography can identify structural causes of outlet obstruction and may be useful when anorectal manometry (ARM) and balloon expulsion testing (BET) are equivocal or additional anatomic detail is required; however, MRD does not replace evacuation proctography (EP) as the reference standard.

MRD may serve as a triage test but has technical variability and may have lower diagnostic yield compared to EP.

EGG/BSGM stance: Conventional electrogastrography (EGG) lacks convincing evidence of diagnostic accuracy or impact on patient management; emerging body surface gastric mapping (BSGM) demonstrates improved signal characteristics and symptom correlation versus low-resolution EGG but clinical utility for improving outcomes is unproven.

Evidence-based coverage considerations

Evidence summary and implied coverage stance based on available literature and guideline positions:

BSGM/EGG evidence summary: BSGM demonstrates improved signal characteristics, greater symptom correlation, and higher patient-level classification accuracy compared to traditional low-resolution EGG in several observational studies, but methodological heterogeneity and study limitations (small samples, proprietary processing, single‑center designs) persist.

Clinical outcome benefit from BSGM has not been established; additional validation and utility studies are required.

EGG in clinical practice: Systematic reviews find EGG abnormalities in GERD and functional dyspepsia populations but inconsistent symptom correlation and variable techniques; many societies consider EGG experimental and do not recommend routine clinical use for gastroparesis diagnosis.

Routine EGG is not supported as a replacement for reference standard testing.

MI testing evidence summary: Studies using balloon MI catheters or impedance rings report distinct MI patterns among GERD, EoE, and non-GERD groups with promising diagnostic performance in small cohorts, but limitations include small sample sizes, lack of blinding, and homogeneous populations limiting generalizability.

This Medical Policy does not apply to the states listed in the Application section; refer to the state‑specific policies for those states for coverage determinations and any differing requirements.

FLIP (Functional Lumen Imaging Probe) assessments should not be used in routine diagnostic evaluations of gastroesophageal reflux disease and should not be the sole basis for diagnosis or treatment decisions. FLIP is described as a complementary tool for assessing esophagogastric junction opening and esophageal wall stiffness and should be interpreted alongside standard studies and within distinct, disease‑specific protocols.

Current evidence for esophageal mucosal integrity (MI) testing is limited. Systematic reviews by ECRI and Hayes conclude that published studies are small and of low quality, and larger clinical validity and utility studies are needed before MI testing can replace standard diagnostic methods for GERD, eosinophilic esophagitis, or nonacid reflux disease.

Language related to gastric electrical stimulation (GES) therapy has been removed from this policy and relocated to a separate Medical Policy titled “Minimally Invasive Procedures for the Treatment of Upper Gastrointestinal Diseases.” Refer to that policy for coverage and clinical guidance on GES.

Examples of procedures listed as unproven and not medically necessary include: MRI Defecography for constipation/anorectal or pelvic floor disorders; and investigational gastric electrical measurement techniques such as electrogastrography (EGG), electroenterography, and body surface gastric mapping (BSGM). The policy identifies these modalities as lacking sufficient evidence to support routine clinical use.

Electrogastrography (EGG) and related surface gastric electrical measurement techniques have not demonstrated convincing diagnostic accuracy for gastric stasis in clinical practice and lack evidence of positive impact on patient management or outcomes. Major society guidance (AGA) does not recommend routine use of EGG for diagnosis or to direct treatment of gastroparesis.

The American Gastroenterological Association (AGA) does not recommend routine use of electrogastrography (EGG) for the diagnosis or treatment guidance of gastroparesis; recent AGA guidance no longer supports EGG as a standard diagnostic tool.

Functional Lumen Imaging Probe (FLIP) technology is listed among procedures considered unproven and not medically necessary when used to diagnose achalasia. The policy explicitly includes FLIP for achalasia in the list of modalities classified as investigational.

As part of the recent update, specific example listings for cutaneous, mucous, or serosal electrogastrography and electroenterography devices (previously enumerated by name) were removed from the examples list; the policy now references these device types generically rather than by product name.

Procedure, Device and Regulatory Codes

Referenced procedure codesCPT

0779T	Gastrointestinal myoelectrical activity study, stomach through colon, with interpretation and report.
0868T	High-resolution gastric electrophysiology mapping with simultaneous patient-symptom profiling, with interpretation and report.
43499	Unlisted procedure, esophagus.
72195	Magnetic resonance (e.g., proton) imaging, pelvis; without contrast material(s).
72196	Magnetic resonance (e.g., proton) imaging, pelvis; with contrast material(s).
72197	Magnetic resonance (e.g., proton) imaging, pelvis; without contrast material(s), followed by contrast material(s) and further sequences.
76498	Unlisted magnetic resonance procedure (e.g., diagnostic, interventional).
91132	Electrogastrography, diagnostic, transcutaneous.
91133	Electrogastrography, diagnostic, transcutaneous; with provocative testing.

Device product/510(k) identifiersmixed

MYE / FFX	FDA product codes referenced for cutaneous electrogastrography/related devices
QIS	Product code referenced for MiVu MI Testing System
K170833	EndoFLIP 510(k) ID
K230056	MiVu 510(k) Number referenced

Provider Requirements, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization and Affected Codes

Prior authorization may be required for certain advanced or device-dependent procedures referenced in this policy. Verify benefit plan prior authorization rules before scheduling or performing services and include the clinical indication and supporting documentation when submitting a request.

Affected / referenced codes include: 0779T, 0868T, 91132, 91133, 43499, 72195, 72196, 72197, 76498
Prior authorization requirements are governed by the member’s federal, state, or contractual benefit terms; these govern in case of conflict

Prior Authorization

MRI Defecography Prior Authorization Considerations

MRI defecography (MRD) can be useful as a triage or adjunctive study when anorectal manometry (ARM) and balloon expulsion test (BET) are inconclusive or when structural causes are suspected. MRD is not a replacement for fluoroscopic evacuation proctography (EP) as the reference standard. Prior authorization requests for MRD should document prior anorectal testing and the specific clinical indication.

Document prior ARM and BET results and why those were inconclusive before requesting MRD

Clinical Background and Epidemiology

Constipation, fecal incontinence, and gastroparesis are common conditions that may require objective diagnostic testing to define underlying pathophysiology. For gastroparesis, scintigraphy is the reference standard for demonstrating clearly delayed gastric emptying, and validated standardized protocols and adequate imaging duration are necessary for accurate interpretation.

Definitions and Abbreviations

Achalasia — definition entry

TermAchalasia

DefinitionA primary esophageal motor disorder characterized by degeneration of the myenteric plexus leading to impaired relaxation of the esophagogastric junction (EGJ) and loss of organized peristalsis in the esophageal body (ASGE).

Clinical contextIncluded as a defined term in the policy update (See Policy History).

Electrogastrography (EGG) — definition entry

TermElectrogastrography (EGG)

DefinitionA non-invasive method measuring gastric myoelectrical activity using cutaneous electrodes placed on the abdominal skin over the stomach (electrogastrogram).

Policy Revision History

2026-05-01revision

Updated North Carolina application reference link; removed Louisiana-specific language; updated Description of Services, Clinical Evidence, FDA, and References sections; archived prior version CS046.R.

2026-04-01material_changeLatest

Title changed from 'Gastrointestinal Motility Disorders, Diagnosis and Treatment' (template update); removed and relocated gastric electrical stimulation (GES) language to a separate policy; added Functional Lumen Imaging Probe (FLIP) technology for diagnosing achalasia to the list of unproven and not medically necessary procedures; removed examples listing specific EGG/BSGM devices and the MiVu MI system.

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyGastrointestinal Disorders Diagnostic Procedures

Policy CodePolicy CS046.S

Change TypeContent revisions with material additions/removals

Effective DateApr 1, 2026

Next Review Date

Key ActionDocument prior conservative management and objective diagnostic evidence and obtain prior authorization when requesting procedures listed as unproven or experimental.

SourceLink

On This Page

ECRI and other assessments rate current evidence as low quality and recommend further validation and larger clinical studies.

MI testing stance: Preliminary studies of mucosal impedance (MI) testing show distinct patterns across GERD, EoE, and non-GERD populations in small cohorts, but evidence is limited and clinical utility and safety require further study.

ECRI and Hayes reviews conclude additional larger clinical validity and utility studies are needed.

Insufficient evidence of clinical utility to support routine coverage.

Guideline positions: Major GI society guidelines (AGA, ACG) do not endorse routine use of EGG or MI testing as established diagnostic tools and advise that FLIP not be used alone to make diagnoses or guide treatment decisions.

Guideline restraint supports a cautious, investigational/adjunctive stance for these modalities.

Coverage implication: Given limited and evolving evidence plus guideline caution, these modalities should be considered investigational/adjunctive; coverage decisions should require demonstration that test results will change management beyond standard diagnostics.

When considered, prior authorization and documentation of how the test will affect management are recommended.

Note that MRD may confirm rectocele, enterocele, intussusception and can rule out anismus, but EP remains the reference standard

Prior Authorization

Device Clearance and Potential Prior Authorization

Some devices referenced in this policy have received FDA clearance; device-specific coverage and any consequent prior authorization requirements should be confirmed with the plan. FDA clearance alone does not guarantee coverage.

Examples: MiVu/MiVu Mucosal Integrity Testing System (Diversatek) cleared as Class II de novo; FLIP/EndoFLIP is an FDA-regulated measurement tool
Check device-specific product codes and 510(k)/de novo listings when preparing prior authorization requests

Denial Risk

Denial Triggers for Unproven Procedures

Procedures or tests deemed unproven or experimental may be denied when submitted without appropriate clinical justification or when used as a primary diagnostic modality. Submit documentation showing why standard diagnostic pathways are inadequate or why the unproven test is necessary to manage the patient.

Examples of procedures often considered unproven: MRI defecography as a primary replacement for EP, cutaneous/mucosal/serosal electrogastrography/body surface gastric mapping for diagnosing gastroparesis, esophageal mucosal integrity testing as a sole diagnostic test, FLIP used alone to make diagnoses
Prior authorization requests that lack evidence of prior standard testing or clear clinical utility risk denial

Denial Risk

MI Testing Evidence Limitations

Current evidence is insufficient to conclude that esophageal mucosal integrity (MI) testing by electrical impedance is safe and effective as a standalone diagnostic tool for GERD, EoE, or nonacid reflux disease, or for monitoring treatment response. Prior authorization submissions should acknowledge evidence limitations and include corroborating standard diagnostic test results when applicable.

MI testing should not be used as the sole diagnostic test — provide EGD, pH monitoring, biopsy, or other standard test results when available
Document how MI results will change management beyond current standard testing

Note

Conflict with Benefit Plan Requirements

Coverage determinations must follow the member’s federal, state, or contractual benefit plan. If plan terms conflict with this policy, the applicable federal, state, or contractual requirements govern. Verify the member’s benefit terms before pursuing prior authorization or performing services.

Check for state-mandated benefits or specific contractual rider language that may supersede policy
UnitedHealthcare may use third-party tools (e.g., InterQual) to assist in administering benefits; authorization requirements may vary

Documentation Required

Required Clinical Documentation and Adherence to Standard Protocols

Provide complete clinical documentation to support the medical necessity of advanced testing. Ensure adherence to validated, standardized protocols and document prior conservative management and standard diagnostic steps.

Document presenting symptoms, duration, and prior conservative therapies (dietary measures, fiber, laxatives, pelvic floor therapy)
Include results of relevant prior tests (digital rectal exam, ARM, BET, colonic transit studies, EGD, pH testing, biopsies)
For gastroparesis, document objective evidence of delayed gastric emptying (scintigraphy) using standardized meal protocols

Documentation Required

FLIP Documentation and Protocols

FLIP assessments should be performed using disease-specific protocols and considered complementary to, not a replacement for, standard diagnostic tests. FLIP should not be the sole basis for diagnosis or treatment decisions; interpretation should be integrated with endoscopy, manometry, and clinical findings.

Follow established FLIP protocols and analysis paradigms and document the protocol used
Report how FLIP findings influenced management decisions in conjunction with other objective test results

Documentation Required

Pre-imaging Documentation for Defecatory Disorders

When imaging for suspected defecatory disorders is requested (e.g., MRD), document prior anorectal testing and specific symptom details that justify imaging. Imaging is generally reserved for cases where ARM and BET are inconclusive or when structural lesions are suspected.

Include timing and results of ARM and BET and the clinical rationale for proceeding to MRD or fluoroscopic defecography
Describe specific symptoms (e.g., obstructed defecation, visible prolapse, incomplete evacuation) and prior failure of conservative measures

Documentation Required

Required Study Documentation Elements

For tests performed during endoscopy or imaging, include the specific measurements and correlate findings with other diagnostic data. Complete study documentation supports medical necessity and reimbursement.

For MI testing: record MI measurements obtained during endoscopy and correlate with endoscopic findings, pH monitoring and pathology when available
For FLIP: document measured pressures, diameters, protocol used, and how results compare to manometry and clinical presentation
For imaging: include dynamic sequences, findings (rectocele, enterocele, intussusception, anismus), and technique (supine vs seated)

Step Therapy

Stepwise Diagnostic Approach Expected

A stepwise diagnostic approach is expected. Providers should document trials of conservative management and completion of standard diagnostic pathways before performing advanced or experimental tests.

Conservative measures to document may include dietary/lifestyle modifications, fiber therapy, osmotic laxatives, and pelvic floor rehabilitation
Record duration and response to conservative therapies prior to advanced testing

Step Therapy

Stepwise Testing Before Imaging

Before advanced imaging or specialized testing, complete standard anorectal functional testing. ARM and rectal balloon expulsion testing generally suffice to diagnose most defecatory disorders; imaging (barium defecography, fluoroscopic defecography, or MRD) is generally reserved when these tests are inconclusive or when structural pathology is suspected.

Document ARM and BET results and the clinical question that remains unanswered
Reserve imaging for equivocal ARM/BET, suspected structural defects, or preoperative planning

Prior Authorization

Use After Standard Diagnostic Testing

Advanced tests (e.g., MI testing, FLIP, MRD, high-resolution gastric mapping) should be considered only after standard diagnostic testing (EGD, pH monitoring, anorectal tests, scintigraphic gastric emptying) has been completed or shown inconclusive information. Provide documentation showing how advanced testing will alter management.

When ordering advanced tests, attach prior standard test reports and a clear statement of how the advanced test will change clinical management or guide therapy
If advanced testing is sought to avoid an established standard test, justify why the standard test is not feasible or appropriate for the patient

Evidence noteStudies and systematic reviews report inconsistent symptom correlation and limited diagnostic accuracy; conventional EGG is not recommended routinely for gastroparesis diagnosis.

Magnetic Resonance Defecography — definition entry

TermMagnetic Resonance Defecography (MRD)

DefinitionA noninvasive MRI test that obtains images at various stages of defecation to evaluate pelvic floor anatomy, dynamic motion, and rectal evacuation.

Performance contextSystematic reviews show MRD can detect structural causes of outlet obstruction and has high specificity for several findings, but it does not replace evacuation proctography (EP) as the reference standard.

FLIP / EndoFLIP — definition entry

TermFLIP / EndoFLIP (Functional Lumen Imaging Probe)

DefinitionA catheter-based endolumenal system that measures simultaneous pressure and diameter to assess esophagogastric junction opening dynamics, distensibility and esophageal wall stiffness; available since 2009 (EndoFLIP).

GuidanceProfessional societies recommend FLIP be used as a complementary tool and note clinicians should not make diagnosis or treatment decisions based on FLIP assessment alone.

Evacuation Proctography (EP) — definition entry

TermEvacuation Proctography (EP)

DefinitionFluoroscopic defecography technique considered the reference standard for imaging posterior pelvic floor disorders and evaluating evacuation.

Comparative noteEP demonstrates very high sensitivity and specificity for multiple posterior pelvic floor diagnoses and remains the reference standard versus MRD.

BSGM — Body Surface Gastric Mapping short definition

TermBSGM — Body Surface Gastric Mapping (short)

DefinitionNoninvasive multichannel surface mapping of gastric electrical activity used to phenotype gastric motility and correlate with symptoms.

Comparative noteHigh-resolution BSGM shows improved signal characteristics and symptom correlation compared to low-resolution EGG in observational studies, but clinical utility remains under evaluation.

Body Surface Gastric Mapping (BSGM) — extended definition and study references

TermBody Surface Gastric Mapping (BSGM)

Extended definitionA high-resolution, multichannel cutaneous mapping technique that records gastric electrical activity and spatial patterns to phenotype gastric motility and relate biomarkers to symptoms (examples include Gastric Alimetry-type systems).

Key studiesSchamberg et al. (2023) multi-center study (n=178) found BSGM had tighter frequency ranges, greater symptom correlations, and higher patient-level classification accuracy versus EGG; Gharibans et al. (2022) (n=43) showed BSGM expanded phenotyping in chronic nausea/vomiting syndromes.

Evidence cautionECRI rated published evidence for Gastric Alimetry as very low quality and called for larger clinical validity and utility studies; clinical outcome impact is not yet established.

Mucosal Impedance (MI) Testing — definition entry

TermMucosal Impedance (MI) Testing

DefinitionEndoscopic measurement of esophageal epithelial impedance using devices such as balloon catheters or ring sensors to assess mucosal integrity and help distinguish GERD, EoE, and non-GERD conditions.

Validation notePatel et al. (2019) balloon MI study (n=69) reported distinct MI patterns across GERD, EoE and non-GERD groups with potential diagnostic discrimination, but larger validation and clinical utility studies are needed.

Achalasia (updated) — added as a defined term in the policy update

TermAchalasia (updated)

Policy changeAchalasia was added as a defined term in the policy update (Definitions section).

Definition (policy text)A primary esophageal motor disorder of unknown etiology characterized by degeneration of the myenteric plexus, resulting in impaired relaxation of the EGJ and loss of organized peristalsis.

FLIP (updated) — Functional Lumen Imaging Probe (FLIP) added as a defined term in the policy update

TermFLIP (updated) — Functional Lumen Imaging Probe (FLIP)

Policy changeFunctional Lumen Imaging Probe (FLIP) was added as a defined term in the policy update and is listed among procedures considered unproven/not medically necessary for diagnosing achalasia.

Definition (policy text)A catheter-based endoscopic system designed to assess esophageal motility and the distensibility index at the esophagogastric junction by measuring simultaneous pressure and diameter; FLIP/EndoFLIP has been available since 2009.